Long-term follow-up of cervical cancer incidence after normal cytological findings.

cervical cancer cervical screening cytology incidence rate interval cancers

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 Feb 2024
Historique:
received: 19 07 2023
accepted: 07 08 2023
pubmed: 11 9 2023
medline: 11 9 2023
entrez: 11 9 2023
Statut: ppublish

Résumé

An increase in cervical cancer incidence in Sweden from 2014 to 2015 has been attributed to an increase in false-negative cytological findings before cancer diagnoses. Years later, we performed a long-term follow-up to investigate whether the problem persisted. At each calendar year from 2016 to 2020, we identified women with prior normal cervical screening results through linkage to the Swedish National Cervical Screening Registry. We reported their incidence rates (IRs) of invasive cervical cancer in consecutive years and compared the IRs over time. For the years 2016 to 2020, there was no overall change in cervical cancer incidence after two normal cytology in the last two screening intervals. However, there was a further 62% increase among women 50 to 60 years of age with normal cytology in the past two screening intervals. The incidence rate of cervical cancer was high among nonscreened women and low among HPV-screened women with negative results, with no trends over time. Our results imply that the previously reported decrease in sensitivity of cervical cytology is persisting. Although primary cytology screening is no longer used, cytology is used in triaging among HPV-positive women. Our findings suggest that improved triaging is needed, for example, improved quality assurance and/or use of alternative triage tests.

Identifiants

pubmed: 37694922
doi: 10.1002/ijc.34723
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

448-453

Subventions

Organisme : Swedish Cancer Foundation
ID : 20 1199 UsF 02 H

Informations de copyright

© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Cervical Cancer Elimination Initiative. https://www.who.int/initiatives/cervical-cancer-elimination-initiative. Accessed January 16, 2023
Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.
Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-532.
Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49:3262-3273.
Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111:965-969.
Dillner J, Sparén P, Andrae B, Strander B. Livmoderhalscancer ökar Hos Kvinnor Med Normalt Cellprov. http://lakartidningen.se/Klinik-och-vetenskap/Rapport/2018/06/Livmoderhalscancer-okar-hos-kvinnor-med-normalt-cellprov/. Accessed January 16, 2019.
Statistik om cancer. Socialstyrelsen. https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/cancer/. Accessed November 12, 2020.
Wang J, Andrae B, Strander B, Sparén P, Dillner J. Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study. Acta Oncol. 2020;59:988-993.
Edvardsson H, Wang J, Andrae B, Sparén P, Strander B, Dillner J. Nationwide rereview of normal cervical cytologies before high-grade cervical lesions or before invasive cervical cancer. Acta Cytol. 2021;65:1-8.
Sasieni P, Cuzick J. Routine audit is an ethical requirement of screening. BMJ. 2001;322:1179.
Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a Nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622-629.
Wang J, Elfström KM, Andrae B, et al. Cervical cancer case-control audit: results from routine evaluation of a nationwide cervical screening program. Int J Cancer. 2020;146:1230-1240.
Elfström KM, Sparén P, Olausson P, Almstedt P, Strander B, Dillner J. Registry-based assessment of the status of cervical screening in Sweden. J Med Screen. 2016;23:217-226.
The Swedish National Cervical Screening Registry. Swedish National Cervical Screening Registry: Annual Report 2021. https://nkcx.se/templates/_rsrapport_2021.pdf Accessed February 28, 2022.
Wang J, Andrae B, Sundström K, et al. Effectiveness of cervical screening after age 60 years according to screening history: nationwide cohort study in Sweden. PLoS Med. 2017;14:e1002414.
Lynge E, Lönnberg S, Törnberg S. Cervical cancer incidence in elderly women-biology or screening history? Eur J Cancer. 2017;74:82-88.
Lehtinen M, Pimenoff VN, Nedjai B, et al. Assessing the risk of cervical neoplasia in the post-HPV vaccination era. Int J Cancer. 2023;152:1060-1068.
Bouvard V, Wentzensen N, Mackie A, et al. The IARC perspective on cervical cancer screening. N Engl J Med. 2021;385:1908-1918.

Auteurs

Jiangrong Wang (J)

Division of Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Henrik Edvardsson (H)

Department of Pathology and Cancer Diagnostics, Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden.

Björn Strander (B)

Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Regional Cancer Centre West Region Västra Götaland, Gothenburg, Sweden.

Bengt Andrae (B)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Centre for Research and Development, Uppsala University/Region of Gävleborg, Gävle, Sweden.

Pär Sparén (P)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Joakim Dillner (J)

Division of Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Center for Cervical Cancer Elimination, Department of Pathology and Cancer Diagnostics, Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden.

Classifications MeSH